It was found that TIMP1 mRNA in platelets increased for tumor patients, possessing the promising diagnostic performance much higher than CEA and CA199 [93]; Besides, platelet ITGA2B levels were significantly higher in NSCLC patients than in all controls, and the combination of ITGA2B, CEA and stage could predict the overall survival [98]; A similar phenomenon was observed in a pan-cancer study, where platelets mRNA expression profiles were significantly different between tumor patients and healthy volunteers. The gene discussed is ITGA2B; the disease is neoplasm.